Non-Invasive Diagnostic Tests for Non-Alcoholic Fatty Liver Disease

被引:25
作者
Estep, J. M. [1 ,2 ,3 ]
Birerdinc, A. [2 ,3 ]
Younossi, Z. [1 ,2 ,3 ]
机构
[1] Inova Fairfax Hosp, Ctr Liver Dis, Falls Church, VA 22042 USA
[2] George Mason Univ, Mol & Microbiol Dept, Ctr Study Genom Liver Dis, Fairfax, VA 22030 USA
[3] Inova Hlth Syst, Translat Res Inst, Falls Church, VA USA
关键词
Obesity; non-alcoholic fatty liver disease; metabolic syndrome; non-alcoholic steatohepatitis; TRANSIENT ELASTOGRAPHY; INSULIN-RESISTANCE; ADIPOKINE LEVELS; STEATOHEPATITIS; FIBROSIS; SEVERITY; PREDICT; BIOMARKER; MARKER; APOPTOSIS;
D O I
10.2174/156652410790963321
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) is a clinico-pathologic spectrum of conditions ranging from simple steatosis to nonalcoholic steatohepatitis (NASH). Although simple or bland steatosis follows a relatively benign clinical course, NASH can potentially progress to cirrhosis (approximately 10 to 15 percent) and hepatocellular carcinoma. NAFLD occurs in an estimated 25 to 30 percent of the US general population, while NASH is reported in 2 to 3 percent of the population. Even though common explanation for the increased prevalence of NAFLD is the increased rate of obesity, the risk of developing NAFLD and NASH is not limited to overweight and obese individuals. Currently, the only way to diagnose NASH or to assess the stage of fibrosis is by obtaining a liver biopsy. Liver biopsy is invasive, expensive, and associated with potential risks, including post biopsy pain, bleeding, organ perforation, and even death; serious complications can occur in 0.3 percent of liver biopsies with 0.01 percent being fatal. This review examines the current strategies for development of the non-invasive techniques that will one day replace liver biopsy and serve as a non-invasive gold standard for the diagnosis and staging of NASH.
引用
收藏
页码:166 / 172
页数:7
相关论文
共 47 条
[1]  
Adams Leon A, 2007, Clin Liver Dis, V11, P25, DOI 10.1016/j.cld.2007.02.004
[2]   Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis [J].
Albano, E ;
Mottaran, E ;
Vidali, M ;
Reale, E ;
Saksena, S ;
Occhino, G ;
Burt, AD ;
Day, CP .
GUT, 2005, 54 (07) :987-993
[3]  
Bahcecioglu IH, 2005, HEPATO-GASTROENTEROL, V52, P1549
[4]   Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease [J].
Caldwell, SH ;
Oelsner, DH ;
Iezzoni, JC ;
Hespenheide, EE ;
Battle, EH ;
Driscoll, CJ .
HEPATOLOGY, 1999, 29 (03) :664-669
[5]   A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis [J].
Calvert, Valerie S. ;
Collantes, Rochelle ;
Elarinv, Hazem ;
Afendy, Arian ;
Baranova, Ancha ;
Mendoza, Michael ;
Goodman, Zachary ;
Liotta, Lance A. ;
Petricoin, Emanuel F. ;
Younossi, Zobair M. .
HEPATOLOGY, 2007, 46 (01) :166-172
[6]  
CALVERT VS, 2007, HEPATOLOGY, V46, P1315
[7]   Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease [J].
Charlton, Michael ;
Angulo, Paul ;
Chalasani, Naga ;
Merriman, Ralph ;
Viker, Kimberly ;
Charatcharoenwitthaya, Phunchai ;
Sanderson, Schuyler ;
Gawrieh, Samer ;
Krishnan, Anuradha ;
Lindor, Keith .
HEPATOLOGY, 2008, 47 (02) :484-492
[8]   Nonalcoholic Steatohepatitis Is Associated with Altered Hepatic MicroRNA Expression [J].
Cheung, Onpan ;
Puri, Puneet ;
Eicken, Christoph ;
Contos, Melissa J. ;
Mirshahi, Faridoddin ;
Maher, James W. ;
Kellum, John M. ;
Min, Haeki ;
Luketic, Velimir A. ;
Sanyal, Arun J. .
HEPATOLOGY, 2008, 48 (06) :1810-1820
[9]   Impulsivity as a mediator in the relationship between depression and problem gambling [J].
Clarke, D .
PERSONALITY AND INDIVIDUAL DIFFERENCES, 2006, 40 (01) :5-15
[10]   Nonalcoholic fatty liver disease and the epidemic of obesity [J].
Collantes, R ;
Ong, JP ;
Younossi, ZM .
CLEVELAND CLINIC JOURNAL OF MEDICINE, 2004, 71 (08) :657-664